FREE Account Opening + No Clearing Fees
Loading...

Mankind Pharma IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 12 1 0 0 5
% 66.67 5.56 0.00 0.00 27.78

Mankind Pharma IPO Analysis By Brokers/Analysts

Mankind Pharma IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Mankind Pharma IPO is 44. Their analysis recommends Avoid, however active risk seekers can try for the IPO.

Reviewer Rating Score Rating
Capital Market 44 Avoid, however active risk seekers can try

Mankind Pharma IPO Review by Dilip Davda (May apply)

[Dilip Davda]  A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective. Read detail review...

Mankind Pharma IPO Peer Comparison

Mankind Pharma Limited peer comparison with similar listed entities. (Consolidated) (As on March 31, 2022)

Company NameEPS (Rs)NAV (per share) (Rs)P/E (x)RoNW (%)
EPS BasicEPS Diluted
Mankind Pharma Limited33.2035.78153.6523.29
Sun Pharmaceuticals Industries Limited13.60200.1071.546.82
Cipla Limited31.17258.3228.1812.08
Zydus Lifesciences Limited43.83166.0510.9526.40
Torrent Pharmaceutical Limited22.97175.8966.2513.06
Alkem Laboratories137.63722.4423.0319.05
JB Chemicals & Pharmaceuticals Limited49.82240.8339.4818.06
Eris Lifesciences Limited29.88140.3919.1021.28
Ipca Laboratories Limited34.85216.4722.3816.10
Abbott India Limited375.861,327.0056.1928.32
Glaxosmithkline Pharmaceuticals Limited100.04157.1957.0363.64
Dabur India Limited9.8147.4154.5520.75
Procter & Gamble Health Limited116.00371.3942.2731.23
Zydus Wellness Limited48.54761.2631.116.38

Notes for listed peers:

  1. Diluted EPS is sourced from the financial statements of the respective company for the year ended.
  2. P/E Ratio has been computed based on the closing market price of equity shares on the National Stock Exchange of India Limited on March 24, 2023, divided by the Diluted EPS.
  3. For listed peers, RoNW is computed as profit after tax for the year divided by closing net worth. Net worth has been considered as the total equity attributable to equity holders.
  4. Net Asset Value ("NAV") is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2022.
  5. For Proctor & Gamble Health Limited, the latest financial statements are for the year ended June 30, 2022. Accordingly, revenue from operations, EPS, RoNW, and NAV pertain to the year ending June 30, 2022.
  6. Torrent Pharmaceuticals Limited has announced a 1:1 bonus issue with an ex-bonus date on July 08, 2022. Accordingly, Diluted EPS for the year ended March 31, 2022, has been adjusted to reflect the bonus issue.

Mankind Pharma IPO Review by Members

Mankind Pharma IPO Reviews, analysis and views by popular members. Read Mankind Pharma Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Mankind Pharma IPO Review Summary by Members

Review By Apply May Apply Neutral Avoid
Count 9 0 4 12
% 36.00 0.00 16.00 48.00
Clear Search
Member Review
PURSHOTTAMDASS CHHAJER

Avoid

Very high premium

I Like It. 1

April 26, 2023 9:10:54 AM
harit

Neutral

Nothing much left on the table.
Big size IPO.
New HNI rules.
Recent listings are not giving profit.
GMP below 10%

I Like It. 4

April 25, 2023 4:45:29 PM
CautiousInvestor

Avoid

The issue is too pricey. There is nothing left for the investors on the table. Company fundamentals are good so, we can purchase from the secondary market at a cheaper price after listing.

I Like It. 1

April 25, 2023 3:04:12 PM
πŸ”₯ IPO CALLING πŸ”₯
IPO Mentor IPO Mentor (900+ Posts, 600+ Likes)

Apply for Short Term at Upper Price Band

Applay

I Like It. 1

April 25, 2023 2:59:12 PM
RAJENDRA BAGARIA

Neutral

High Price
No listing gain difrence

I Like It. 2

April 25, 2023 10:46:16 AM
ATRS

Apply for Long Term at Cut-off Price

This company is completely focussed on domestic market which will give consistent growth. If it can maintain its past CAGR, it will give very good profit in long term.

I Like It. 1

April 25, 2023 10:10:27 AM
πŸ‘‰ Are CIRCUIT (200+ Posts)

Apply for Listing Gain at Cut-off Price

Go long only company is surprise you with March result. So don't go with market negativity.
As per me it is 100% long and if want to sell then 55 is range to keep in mind.

I Like It. 1

April 24, 2023 6:10:59 PM
PB

Avoid

Highly priced

I Like It. 3

April 24, 2023 3:04:48 PM
Ravi Bharti

Avoid

Low profit at time of listing according GMP.

I Like It. 1

April 22, 2023 9:17:49 AM
Multibagger

Avoid

Hugely overpriced. Avoid like Corona

I Like It. 1

April 21, 2023 10:09:51 PM
Liger
Top Contributor Top Contributor (300+ Posts, 500+ Likes)

Neutral

Wait for post-listing correction to accumulate for long term.

I Like It. 1

April 21, 2023 10:40:43 AM
ruralurban

Apply for Long Term at Cut-off Price

This is a portfolio stock. Any one who can buy this kind of company for long time will have positive surprise in coming periods. I think applying minimum lot for long term is very good for health of our portfolio.

April 20, 2023 10:31:16 PM
HARSH ANKANATH

Avoid

EXISTING INVESTORS IN MANKIND PHARMA GET RICH
HIGH VALUATION
LITERALLY AN ATTEMPT TO PROP UP THE COMPANY VALUE BY OUTSIDE MONEY

I Like It. 2

April 20, 2023 8:18:58 PM
Niceone

Avoid

SELLER 65 NEAR MANKIND. NOTHING WILL HAPPAND IN THIS IPO

April 20, 2023 6:28:55 PM
Shahukaar Saa (300+ Posts)

Apply for Listing Gain at Cut-off Price

60 to 70 % maal bech ke apply karo...
mandi ki asha 75% teji ki asha 25% he...
4300 cr. + full ofs + 35% retail + 1080 rs. value ... ye sab kuch kaam ka nahi , jo bhi kaam ka he wo papi ka maths he jisme ye kuch set nahi hota.. to becho aur aram karo..

I Like It. 1

April 20, 2023 5:23:22 PM
RAVZ

Avoid

THe issue is such a huge OFS. Nothing foes to the company. Also price band is very high. Nothing left on the table for investors. Pure OFS of this size implies company gets nothing from IPO.

Avoid this Ipo at any cost and teach lesson to greedy promoters. Let them buy their own IPO to save face.

I Like It. 4

April 19, 2023 9:35:12 AM
Abhijeet Kumar

Avoid

It is a big size IPO where the only purpose is to give exit to existing investor at big profit. So caution is warranted in applying in it. Many good pharma companies have fallen sharply and are better to buy. Dont go by gmp as seen in may past ipo it will vanish when issue closes

I Like It. 2

April 18, 2023 1:21:29 AM
B.M.SURANA
IPO Guru IPO Guru (2500+ Posts, 4600+ Likes)

Neutral

Isse Kam PE mein Secondary Market mein Acchi Pharma companies Mil jayegi.
Jinka 56 inches ka kaleja hai wo hi........

I Like It. 3

April 17, 2023 9:12:06 PM
BuLLz EyE
IPO Mentor IPO Mentor (800+ Posts, 1100+ Likes)

Avoid

Overpriced

I Like It. 1

April 16, 2023 10:53:50 AM
IProfitO
Top Contributor Top Contributor (200+ Posts, 100+ Likes)

Apply for Long Term at Upper Price Band

It will be a blockbuster ipo .Forward pe will be less than 25 which is less compared to its peers .

April 16, 2023 10:00:07 AM
Mohammed Osman Hadi

Apply for Long Term at Upper Price Band

There us good y-o-y growth of both revenue and profit so Subscribe at upperband

I Like It. 1

April 15, 2023 5:22:45 PM
GrowMoreInv

Avoid

Very Expensive IPO with FV of 1 INR.
Avoid such IPOs which have FV of less then 5 INR.

I Like It. 1

April 15, 2023 11:21:53 AM
newgen consultancy

Apply for Long Term at Upper Price Band

Strong growth outlook with almost 50% + market share in its core products
15% listing gain possible but try for long term
Lamba sochke agar listing me ban jaye to aur acchha hoga

I Like It. 1

April 14, 2023 7:16:56 PM
Baron

Avoid

Very high borrowings

I Like It. 3

April 14, 2023 1:39:02 PM
Amit Surana (400+ Posts)

Apply for Long Term at Cut-off Price

one of the top and old pharma company....
hopefully it should not disappoint investor :)

April 14, 2023 11:18:16 AM

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.